Clinical Trials Browser

Phase 2/3 × Not yet recruiting × nimotuzumab × Clear all

NCT06409429 2024-05-10

Nimotuzumab Combined With GX as Postoperative Adjuvant Therapy in Pancreatic Cancer

Phase 2/3 Not yet recruiting

Gastrointestinal

Pancreatic Neoplasms